China's proposed clinical reforms address industry concerns

China’s proposed reforms to its clinical trial review and approval process could address calls from industry for consistent regulation of investigator-initiated clinical trials.

Investigator-initiated trials are approved by local institutional review boards unlike in the U.S., where requirements

Read the full 376 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE